The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Advances in TIL therapy for melanoma and solid tumors highlighted at ASCO 2026
Omid Hamid, MD, of The Angeles Clinic and Research Institute, discusses emerging advances in tumor-infiltrating lymphocyte (TIL) therapy for melanoma and other solid tumors presented at ASCO 2026, including IL-15–enhanced TIL approaches designed to reduce toxicity while maintaining high response rates. Dr Hamid also highlights expanding applications of TIL therapy in traditionally immunotherapy-resistant tumors. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
